Stockscreener 앱 받기
1.435
3.31%
0.045
전일 마감가:
$1.39
열려 있는:
$1.44
하루 거래량:
1.28M
Relative Volume:
0.92
시가총액:
$52.58M
수익:
$832.00K
순이익/손실:
$-135.12M
주가수익비율:
-0.2356
EPS:
-6.09
순현금흐름:
$-124.69M
1주 성능:
+5.59%
1개월 성능:
-26.73%
6개월 성능:
-34.73%
1년 성능:
-85.74%
1일 변동 폭
$1.4101
$1.48
1주일 범위
$1.30
$1.48
52주 변동 폭
$1.30
$12.33
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
명칭
Inovio Pharmaceuticals Inc
전화
(858) 410-3134
주소
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
INO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.4338 | 69.31M | 832.00K | -135.12M | -124.69M | -6.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.84 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.43 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.08 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.50 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
292.00 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-09 | 개시 | Piper Sandler | Overweight |
| 2024-05-14 | 개시 | Stephens | Overweight |
| 2024-01-25 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-11-09 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2022-11-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-07-19 | 재개 | RBC Capital Mkts | Sector Perform |
| 2022-05-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-12-29 | 재개 | Jefferies | Hold |
| 2021-09-10 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-06-24 | 개시 | Jefferies | Hold |
| 2021-03-23 | 개시 | BofA Securities | Neutral |
| 2021-02-12 | 개시 | Oppenheimer | Outperform |
| 2020-11-17 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2020-11-10 | 업그레이드 | ROTH Capital | Sell → Neutral |
| 2020-09-28 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2020-09-28 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-07-01 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2020-06-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-06-26 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-05-21 | 개시 | The Benchmark Company | Buy |
| 2020-04-30 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2020-03-13 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-03-13 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-12-19 | 개시 | ROTH Capital | Buy |
| 2018-02-15 | 재확인 | Maxim Group | Buy |
| 2017-10-18 | 개시 | RBC Capital Mkts | Outperform |
| 2017-09-06 | 개시 | Citigroup | Buy |
| 2017-06-08 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2017-05-24 | 재확인 | Maxim Group | Buy |
| 2017-03-16 | 업그레이드 | Maxim Group | Hold → Buy |
| 2017-03-16 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
모두보기
Inovio Pharmaceuticals Inc 주식(INO)의 최신 뉴스
What analysts say about Inovio Pharmaceuticals Inc. stockRecord-breaking gains - Autocar Professional
What drives Inovio Pharmaceuticals Inc. stock priceBreakthrough capital growth - Autocar Professional
Is Inovio Pharmaceuticals Inc. a good long term investmentTremendous wealth creation - jammulinksnews.com
Inovio Pharmaceuticals Inc. Stock Analysis and ForecastTriple-digit returns - jammulinksnews.com
What makes Inovio Pharmaceuticals Inc. stock price move sharplyFree Smart Money Stock Analysis - beatles.ru
INOVIO to Present DNA Medicine Innovations for Rare Diseases at Orphan Drug Summit - MyChesCo
Inovio wins new Overweight at Piper Sandler on potential FDA nod for lead drug - MSN
INOVIO Announces Pricing of $25 Million Public Offering - Kilgore News Herald
Inovio Pharmaceuticals (INO) Set for Growth With Potential FDA N - GuruFocus
Inovio stock on Piper Sandler's bullish view (INO:NASDAQ) - Seeking Alpha
This Wingstop Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Piper Sandler Initiates Inovio Pharmaceuticals at Overweight With $5 Price Target - MarketScreener
Inovio (INO) Gains Favorable Analyst Rating with $5 Price Target - GuruFocus
Inovio Pharmaceuticals Announces Public Offering Agreement - The Globe and Mail
INOVIO Pharmaceuticals: Pioneering Rare Disease Therapies with DNA-Encoded Antibodies - AInvest
INOVIO to Present at Upcoming Scientific Conference - StreetInsider
INOVIO to Present at Upcoming Scientific Conference | INO Stock News - GuruFocus
INOVIO Announces Public Offering of Common Stock and Warrants - MSN
Inovio Pharmaceuticals announces proposed public offering of common stock and warrants - MSN
Inovio Pharmaceuticals Plunges 29.44% on $25M Offering - AInvest
Inovio Stock’s Unexpected Dive - StocksToTrade
INOVIO Announces Pricing of $25 Million Public Offering | INO Stock News - GuruFocus
Inovio prices $25 million public offering of common stock and warrants - Investing.com
Inovio prices $25 million public offering of common stock and warrants By Investing.com - Investing.com South Africa
INOVIO announces proposed public offering of common stock By Investing.com - Investing.com South Africa
INOVIO Pharma Announces Proposed Public Offering - Nasdaq
Inovio Pharmaceuticals (INO) Announces Public Offering Plan - GuruFocus
Inovio Pharma dives on equity offering plans - TradingView
Inovio Pharmaceuticals stock plunges after announcing public offering - Investing.com
Inovio Pharmaceuticals, Inc.(NasdaqCM:INO) dropped from Russell Small Cap Completeness Index - MarketScreener
Inovio Pharmaceuticals, Inc.(NasdaqCM: INO) dropped from Russell 3000 Value Index - MarketScreener
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q1 2025 Earnings Call Transcript - MSN
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - AllSides
Human DNA Vaccines Market Set to Witness Breakthrough Advances - openPR.com
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Position Boosted by Bank of America Corp DE - Defense World
Deutsche Bank AG Has $164,000 Stock Holdings in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Defense World
Northern Trust Corp Grows Holdings in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Defense World
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio’s SWOT analysis: dna immunotherapy firm faces crucial year for stock - Investing.com Australia
Inovio Pharmaceuticals Inc (INO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.03%
0.17%
자본화:
|
볼륨(24시간):